Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX04-O in wAMD
NCT04993352Phase 2Completed
- Sponsor
- Henlius
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HLX04-O in exudative macular degeneration, sponsored by Henlius. Primary endpoints: Safety events at 4 weeks and Mean change of letters from baseline in the BCVA at 12 weeks. Started Jul 2021; status: completed.
02
Drugs
HLX04-O
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04993352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993352.